Wednesday, October 14, 2026

ID Logistics Trades at 4x DCF Value as Consensus Targets Diverge by €395

ID Logistics Group trades at €354.0 on Euronext Paris — 4.06x its DCF intrinsic value of €87.24. The consensus analyst target of €482.57 stands more than five times above the DCF valuation, suggesting analysts are pricing in growth assumptions not supported by discounted cash flow fundamentals. A reversion to fundamental pricing implies downside exceeding 75%.

LM Salvado
LM Salvado

May 19, 2026

ID Logistics Trades at 4x DCF Value as Consensus Targets Diverge by €395
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

ID Logistics Group trades at significant capitalon Euronext Paris — 4.06 times its DCF intrinsic value of significant capital.1 If pricing reverts toward cash flow fundamentals, implied downside exceeds 75%.1

The valuation gap between market price and DCF output is wide. The consensus analyst target stands at significant capital— more than five times the DCF figure.1 That spread suggests the market is pricing in growth rates or margin trajectories that discounted cash flow models do not support.

DCF analysis discounts projected free cash flows to present value using a required rate of return. When a stock trades at multiples of its DCF output, the market implicitly bets on accelerated growth, margin expansion, or both. For ID Logistics, bridging the gap between significant capitalintrinsic value and significant capitalarket price requires compounding assumptions well beyond what cash flow models currently reflect.1

European third-party logistics operators have benefited from e-commerce expansion and supply chain outsourcing. ID Logistics operates warehousing and distribution services across multiple geographies. Sector tailwinds are real — but sector strength does not automatically close a DCF gap of this magnitude.

Consensus targets of significant capitalimply further upside from current levels.1 The DCF model places fair value below €90.1 A spread this wide, on a mid-cap European name, is unusual and warrants scrutiny of the assumptions embedded in both views.

The risk profile is asymmetric. Consensus growth delivers upside. But if free cash flow generation disappoints — or if discount rates remain elevated — the gap closes downward. With implied downside above 75% in a mean-reversion scenario, the margin of safety is thin for long positions initiated near current prices.1

ID Logistics is listed on Euronext Paris with exposure to logistics, supply chain, and warehousing. The DCF risk assessment was conducted on May 19, 2026.1

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com